LEXICON PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-03-03
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $600.00K.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $200.00K, a 90.00% decline from fiscal 2017.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $2.00M, a 17.65% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 |
| 2021-12-31 | $600.00K 10-K · filed 2022-03-10 |
| 2018-12-31 | $200.00K 10-K · filed 2021-03-12 |
| 2017-12-31 | $2.00M 10-K · filed 2020-03-12 |
| 2016-12-31 | $1.70M 10-K · filed 2019-03-15 |
| 2015-12-31 | $35.00K 10-K · filed 2018-03-01 |
| 2014-12-31 | $43.00K 10-K · filed 2017-03-06 |
| 2013-12-31 | $325.00K 10-K · filed 2016-03-11 |
| 2012-12-31 | $462.00K 10-K · filed 2015-03-12 |
| 2011-12-31 | $63.00K 10-K · filed 2014-03-07 |
| 2010-12-31 | $1.10K 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |